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Objectives: Allopurinol is the most widely prescribed serum uric acid-lowering therapy (ULT) in gout. To
achieve serum uric acid (sUA) concentrations associated with clinical beneﬁt, allopurinol is serially
uptitrated with sUA monitoring. Suboptimal dosing is a key contributor to poor clinical outcomes, but few
data are available on the safety and efﬁcacy of dose-titrated allopurinol, particularly at doses 4300 mg/d.
The objective of this open-label study was to investigate the safety and efﬁcacy of allopurinol under
conditions where investigators were encouraged to titrate to optimal, medically appropriate doses.
Methods: Long-term Allopurinol Safety Study Evaluating Outcomes in Gout Patients (LASSO) was a large,
6-month, multicenter study of allopurinol (NCT01391325). Adults meeting American Rheumatism
Association Criteria for Classiﬁcation of Acute Arthritis of Primary Gout and Z2 gout ﬂares in the previous
year were eligible. Investigators were encouraged (but not required) to titrate allopurinol doses to achieve
target sUA o 6.0 mg/dL. The primary objective was evaluation of the safety of dose-titrated allopurinol by
clinical and laboratory examinations at monthly visits. Secondary objectives included sUA-lowering
efﬁcacy and gout ﬂare frequency.
Results: Of 1735 patients enrolled, 1732 received Z1 allopurinol doses. The maximal daily allopurinol dose
during study was o300 mg in 14.4%, 300 mg in 65.4%, and 4300 mg in 20.2% of patients; dosing duration
was 115.5, 152.0, and 159.7 days, respectively. Overall, baseline demographic characteristics and
comorbidity rates were similar across these three categories, but patients receiving 4300-mg maximal
dose had more severe gout. Treatment-emergent adverse events possibly related to allopurinol occurred in
15.2%, 9.5%, and 11.4% of patients in the o300-, 300-, and 4300-mg categories, respectively. Rash
incidence was low (1.5%) and allopurinol hypersensitivity syndrome was not reported. No clinically
meaningful changes occurred in laboratory values. sUA o 6.0 mg/dL at month 6 was achieved by 35.9% of
patients overall: 22.4%, 35.0%, and 48.3% in dosing categories o300, 300, and 4300 mg, respectively.
Conclusions: This large multicenter study found that the allopurinol dose-titration strategy was well
tolerated, without new safety signals emerging over 6 months. However, despite encouragement to treat to
target, signiﬁcant proportions of patients did not achieve target sUA.
& 2015 The Authors. Published by Elsevier HS Journals, Inc. This is an open access article under the CC BY-
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The incidence and prevalence of gout are increasing worldwide,
with over 8 million individuals affected in the USA alone [1]. This
increase appears due in part to changes in demographics and diet
and to increased incidences of comorbidities associated with
hyperuricemia or gout, including hypertension, obesity, metabolic
syndrome, and chronic kidney disease [2,3].access article under the CC BY-NC-ND license
M.A. Becker et al. / Seminars in Arthritis and Rheumatism 45 (2015) 174–183 175Gout is a chronic arthritic disease characterized by hyperurice-
mia [i.e., serum uric acid concentrations (sUA) exceeding 6.8 mg/dL,
the limit of urate solubility] and by symptoms and signs resulting
from inﬂammatory responses to monosodium urate crystals depos-
ited in joints and associated connective tissues from extracellular
ﬂuids saturated for uric acid. Although hyperuricemia is necessary
(but not alone sufﬁcient) for clinical onset of gout, it is the major
risk factor for disease expression and progression [3]. Accordingly,
guidelines produced by the European League against Rheumatism
(EULAR) [4,5] and the American College of Rheumatology (ACR) [6]
recommend achieving and maintaining a target sUA o 6 mg/dL
(o360 mmol/L) for disease control in most gout patients.
Allopurinol is the most widely prescribed ﬁrst-line sUA-low-
ering agent in gout [7–10]. Guidelines for allopurinol dosing
recommend a starting dose not exceeding 100 mg/d to reduce risk
of allopurinol hypersensitivity syndrome (AHS). AHS is associated
with the potential for severe morbidity (including rash, fever,
eosinophilia, hepatic abnormalities, and acute renal failure) and a
mortality rate of 2025% [6]. Subsequent dose titration in incre-
ments of 100 mg/d every 24 weeks with sUA monitoring is
recommended to guide achievement and maintenance of a target
sUA, usually o6 mg/dL [6]. Allopurinol is approved for use in
doses as high as 800 mg (USA) or 900 mg (EU) daily [11], but in
practice few patients receive daily doses above 300 mg [12].
Although used in gout treatment for nearly 50 years, there are
limited data on the safety and efﬁcacy of dose-titrated allopurinol,
particularly for doses exceeding 300 mg/d. Long-term Allopurinol
Safety Study Evaluating Outcomes in Gout Patients (LASSO) was an
open-label, 6-month study of the safety and sUA-lowering efﬁcacy
of allopurinol in adults with gout (NCT01391325), where inves-
tigators were encouraged (but not required) to titrate allopurinol
to effect—that is, a dose achieving sUA o6 mg/dL.Table 1
Inclusion and exclusion criteria in LASSO
Inclusion criteria
1. 1885 years of age
2. Male or female; females of childbearing potential who were sexually active mu
and could neither be pregnant nor lactating from screening throughout the du
3. Patient met the diagnosis of gout according to the American Rheumatism Asso
4. Patients not on a ULT must have had an sUA Z 8.0 mg/dL at screening
5. Patients on concomitant ULT must have had an sUA Z 6.5 mg/dL at screening
6. Patient must have had at least 2 gout ﬂares in the past year
7. Patient was willing and able to give informed consent and adhere to visit/prot
Exclusion criteria
1. Baseline sUA o 6.5 mg/dL
2. More than 14 drinks of alcohol per week [e.g., 1 drink ¼ 5 oz (150 mL) of win
3. History or suspicion of drug abuse
4. History of myositis or rhabdomyolysis
5. History of autoimmune disease requiring systemic treatment
6. Known or suspected human immunodeﬁciency virus (HIV), hepatitis C antibod
7. History of malignancy within the previous 5 years (with the exception of nonme
cervical dysplasia, or treated in situ Grade 1 cervical cancer)
8. Myocardial infarction, unstable angina, New York Heart Association (NYHA) cla
9. Uncontrolled hypertension (systolic pressure above 160 mmHg or diastolic pre
10. Estimated creatinine clearance at screening o30 mL/min by CockcroftGault
11. Kidney or other organ transplant
12. Hemoglobin o10 g/dL (males) or o9 g/dL (females)
13. Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) 4 2  up
14. Gamma-glutamyl transferase (GGT) 4 3  upper limit of normal (ULN)
15. Active peptic ulcer disease requiring treatment
16. History of xanthinuria, active liver disease, or hepatic dysfunction
17. Requires therapy with any other sUA-lowering medication, other than allopuri
18. Unable to take gout ﬂare prophylaxis of either colchicine or NSAID due to contr
19. Received an investigational medication within 8 weeks or 5 half-lives (whiche
20. Previously participated in a clinical study involving lesinurad (RDEA594) or RD
21. Previously received pegloticase
22. Known hypersensitivity or allergy to allopurinol
23. Any other medical or psychological condition that, in the opinion of the Investi
with the patient's ability to comply with the protocol requirements, or to comMethods
Patients
Adults aged 1885 years with a diagnosis of gout by American
Rheumatism Association Criteria for the Classiﬁcation of Acute Arthri-
tis of Primary Gout and at least two gout ﬂares in the previous year
were eligible for study participation. For patients not receiving sUA-
lowering pharmacotherapy (ULT) at screening, the required screening
sUA was Z8.0 mg/dL; for those receiving ULT at screening, an sUA of
Z6.5 mg/dL was required. The choice of the sUA threshold Z8.0mg/dL
in patients not receiving ULT at screening is consistent with that of
earlier trials of febuxostat, which used an sUA threshold Z8.0mg/dL
after washout [13,14]. Since LASSO was primarily a safety trial, patients
on concomitant allopurinol (or other ULT) at screening were permitted
to remain/be initiated on allopurinol and to be uptitrated to goal as
needed, and so they were allowed to be at the lower sUA level of
Z6.5 mg/dL at screening. Only patients receiving a ULT other than
allopurinol at screening had to complete a washout of Z7 days.
Exclusion criteria at screening included a history of allopurinol
intolerance, estimated creatinine clearance (CrCl) o30 mL/min,
hemoglobin o10 g/dL (males) or o9 g/dL (females), 414 drinks
of alcohol per week, and a history of xanthinuria, active liver
disease, or hepatic dysfunction. Complete study inclusion and
exclusion criteria are included in Table 1.
LASSO was conducted in accordance with the Declaration of
Helsinki and consistent with the International Conference on
Harmonization/Good Clinical Practice and was approved by appro-
priate institutional review boards. All patients provided written
informed consent. Where appropriate, LASSO complied with the
Health Insurance Portability and Accountability Act of 1996. The
study was performed between June 2011 and January 2013.st have agreed to use adequate contraception (as determined by the Investigator)
ration of the study
ciation (ARA) Criteria for the Classiﬁcation of Acute Arthritis of Primary Gout
ocol schedules
e, 12 oz (360 mL) of beer, or 1.5 oz (45 mL) of hard liquor]
y (HCV), or hepatitis B antibody (HBsAg) infection
lanoma skin cancer that has been treated with no evidence of recurrence, treated
ss III or IV heart failure, or stroke within the last 12 months
ssure above 95 mmHg)
formula
per limit of normal (ULN)
nol
aindication (e.g., toxicity, renal function, and use of contraindicated medications)
ver is longer) prior to the screening visit for this study
EA806
gator and/or Medical Monitor, might create undue risk to the patient or interfere
plete the study
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The study included a screening and pretreatment period of 21 days
(including, where appropriate, washout) and initiation, re-initiation, or
continuation at day 1 of allopurinol treatment for up to 6 months
(Fig. 1). Dose initiation and titration recommendations in the study
protocol were to increase the allopurinol dose to reach a target sUA of
o6mg/dL at monthly or more frequent assessments. However, dose
adjustments were at the discretion of investigators in accordance with
local prescribing guidelines to provide a dose of at least 200mg daily.
Allopurinol dose titrationwas not speciﬁcally adjusted in patients with
mild renal impairment (i.e., CrCl, 30–60 mL/min). At completion of
study participation, each patient was categorized for safety and
efﬁcacy analyses into one of three prespeciﬁed allopurinol dosing
categories (category one, o300mg; category two, 300mg; and
category three, 4300mg) according to the maximum total daily
allopurinol dose at any time during study. These dosing categories
were selected to provide adequate patient numbers for analysis.
Patients in each dosing category may thus have received different
allopurinol exposures during the study.
Patients received colchicine (0.5 or 0.6 mg daily) or a non-
steroidal anti-inﬂammatory drug (NSAID, dosed according to local
guidelines) as prophylaxis for gout ﬂares. Patients who developed
intolerance or toxicity to their initial prophylactic regimen could
switch to another medication or discontinue. Patients experienc-
ing a gout ﬂare during screening had their baseline (qualifying)
visits postponed until the ﬂare resolved.
Patients were assessed for allopurinol safety and efﬁcacy at
baseline and monthly visits during study treatment. End-of-study
assessments were recorded when patients completed 6 months of
dosing or discontinued the study prematurely for any reason. The
date and reasons for discontinuation were recorded. Patients with
an inadequate response to allopurinol after at least 8 weeks or
unable to tolerate allopurinol were eligible for participation in
studies of lesinurad, a selective uric acid reabsorption inhibitor
(SURI) in development for treatment of gout [15].Study end points
Primary end point
The primary study end point was the incidence of treatment-
emergent adverse events (TEAEs) reported during titrated doses ofKey inclusion criteria
• Adult gout patients 
 (per ACR criteria with 
and
• Fall into one of the 
 following groups:
 1. On ULT at screening
  – not pegloticase
  – sUA  6.5 mg/dL
 2. Not on ULT at screening 
  – no allopurinol 
   toxicity leading to 
   discontinuation 
  – sUA  8.0 mg/dL
 3. Have never taken ULT
  – sUA  8.0 mg/dL
Patients on ULT 
other than 
allopurinol have 
7 day or longer 
ULT washout 
21 day 
screening 
period
Day 
1
Fig. 1. Open-label design of the LASSO study. aInvestigators may require more visits fo
lowering therapy.allopurinol. AEs with a new onset after allopurinol initiation or
with increased intensity or severity during study were considered
treatment-emergent. TEAEs were coded using the Medical Dic-
tionary for Regulatory Activities (MedDRA) version 14.0 or higher.
Additional safety evaluations included physical examination, vital
signs, electrocardiogram, clinical chemistry, hematology, and uri-
nalysis. An independent cardiovascular (CV) events adjudication
committee assessed TEAEs by prospectively deﬁned criteria for
major adverse cardiovascular events (MACE) and non-MACE CV
end points [16].Secondary end points
Secondary study end points included measurements of sUA-
lowering efﬁcacy and the frequency of gout ﬂares requiring treat-
ment; sUA-lowering efﬁcacy was assessed by the proportion of
patients with sUA o 6 mg/dL at the month 6 visit, the proportions
with sUA o 6, o 5, and o 4 mg/dL at each monthly visit, and the
absolute and percent reductions in sUA from baseline at monthly
intervals; sUA was measured by a central laboratory.
Patients completed an ethics committee-approved diary to
provide information on the incidence and duration of gout ﬂares
requiring treatment. Administration of treatment for ﬂares was
conﬁrmed by review of concomitant medication use.Statistical analysis
The primary objective of the LASSO study was to provide
estimates on the frequencies of TEAEs in patients treated with
allopurinol.
Continuous data were summarized by descriptive statistics
including mean, standard deviation (SD), minimum, and maxi-
mum. Categorical data were summarized by the number and
percentage of patients and by response rates (proportion of
patients who met serum uric acid targets). Selected assessments
included 95% conﬁdence intervals (CIs). As this was an open-label
study of allopurinol with no control arm, no formal statistical
analyses were conducted for any assessment, as these would lack
appropriate statistical validity.
All patients who received at least one dose of allopurinol were
included in both safety and efﬁcacy analyses.Allopurinol (dosed at discretion of investigator
to achieve an optimal, medically appropriate 
dose of 200 mg) 
+ 
Prophylaxis therapy (colchicine or NSAIDs)
After 8 weeks, patients eligible for a lesinurad
phase III study if they:
• had sUA > 6 mg/dL
• were on a stable dose of allopurinol of 
300 mg daily (200 mg for renal impairment)
• developed intolerance to allopurinol  
Month 
1a
Month 
6
Month 
5
Month 
4
Month 
3
Month 
2
r titration or monitoring. ACR, American College of Rheumatology; ULT, uric acid-
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Patient baseline characteristics
Patients were enrolled at 169 study sites in seven countries:
Australia (11 sites), Belgium (1), Canada (6), Germany (2), New
Zealand (7), South Africa (18), and the United States (124). Of 1735
patients enrolled, 1732 received Z1 dose of allopurinol. The 6-
month study period was completed by 1238 patients (71.5%)
(Fig. 2).
Baseline demographic and gout characteristics are shown in
Table 2. Most patients were male and white. Mean age and body
mass index were 51.4 years and 34.41 kg/m2, respectively. Baseline
comorbidities (in 410% of patients) included hypertension
(52.5%), hypercholesterolemia (35.7%), obesity based on medical
history records (29.3%), hypertriglyceridemia (16.1%), and diabetes
mellitus (13.1%). More than half of the patients had mild or
moderately impaired renal function, assessed by CrCl at baseline.
The mean (SD) duration of gout diagnosis was 10.22 (9.2) years,
and tophi were present in 17% of patients. The mean (SD) baseline
sUA was 8.8 (1.7) mg/dL and was Z6 mg/dL in 96.0% of patients.
Prior use of any ULT was reported by 62.0% of patients. At
screening, 32.0% of patients were receiving allopurinol and 1.7%
an alternative ULT.
The mean (SD) daily allopurinol dose during study was 269.5
(111.7) mg over a mean (SD) duration of 148.3 (50.0) days. Only
1.1% of patients received a maximum dose Z700 mg/d and 0.2% of
patients received 900 to o1000 mg/d.  Reasons for dis
Baseline sUA < 6.5 mg/dL
Lost to follow-up, n = 94 (5
Consent withdrawn, n = 79
Adverse event, n = 69 (4.0
Investigator decision, n = 
Treatment failure, n = 35 (
Noncompliance/protocol v
Sponsor decision, n = 7 (.
Gout flare, n = 3 (.2%)
Death, n = 2 (.1%)
N = 17
Enroll
  N = 3
Discontinued prior to
receiving allopurinol
 N = 17
Treated with a
n = 1238 Com
n = 494 Disco
Fig. 2. Study ﬂow. aSubjects who received both colchicine and NSAIDs are not count
population. NSAIDs, nonsteroidal anti-inﬂammatory drugs.Allopurinol dose titration
Details of allopurinol dose titration are provided in Table 3,
which displays shifts in allopurinol daily dosing. Of 986 patients
who received an initial allopurinol dose o200 mg/d, 722 (73%)
were receiving at least 200 mg allopurinol daily at the last sUA
determination, but only 152 (15%) were receiving allopurinol at
4300 mg daily. As also shown in Table 3, of 746 patients who
started the study at allopurinol doses of 200 mg or greater, only
125 (17%) were receiving a higher dose at ﬁnal sUA determination.
Overall, of 1732 patients initiating the study, 937 (54.1%) com-
pleted the study on a higher allopurinol daily dose than at
baseline.
The maximum daily allopurinol dose at any time during study
was o300 mg in 250 patients (14.4%), 300 mg in 1132 patients
(65.4%), and 4300 mg in 350 patients (20.2%). Mean (SD) total
days of dosing were similar in the 4300- and 300-mg categories
[159.7 (35.7) and 152.0 (46.1) days, respectively] and were lower in
the o300-mg category [115.5 (67.7) days]. Patients who received a
maximum dose 4300 mg/d during study had more severe disease
at baseline (i.e., longer gout duration, greater incidence of tophi,
and more gout ﬂares in the prior year; Table 2). The proportion of
patients with baseline CrCl o 60 mL/min was greater in the
o300-mg category (29.2%) than 300-mg (13.8%) and 4300-mg
categories (9.7%). Other baseline characteristics and rates of
comorbidities were similar across dosing categories. Rates of
patient-reported adherence with allopurinol were high and similar
in each dosing category (97.8%, o300-mg; 96.6%, 300-mg; andcontinuation
, n = 116 (6.7%)
.4%)
 (4.6%)
%)
67 (3.9%)
2.0%)
iolation, n = 22 (1.3%)
4%)
35
ed
32
llopurinol:
pleted
ntinued
 N = 1719
Treated with prophylaxisa:
n = 1468 Colchicine
n = 209 NSAID
n = 41 Both
n = 1 Other
ed in the individual counts for colchicine and NSAIDs. Data represents enrolled
Table 2
Baseline demographic and gout characteristics of the study population categorized by maximum daily allopurinol dose and overall
Variable Maximum allopurinol daily dose
o300 mg (n ¼ 250) 300 mg (n ¼ 1132) 4300 mg (n ¼ 350) Total (N ¼ 1732)
Sex [n (%)]
Female 39 (15.6) 69 (6.1) 10 (2.9) 118 (6.8)
Male 211 (84.4) 1063 (93.9) 340 (97.1) 1614 (93.2)
Race [n (%)]
American Indian or Alaska Native 1 (0.4) 11 (1.0) 0 12 (0.7)
Asian 16 (6.4) 58 (5.1) 21 (6.0) 95 (5.5)
Black or African American 28 (11.2) 109 (9.6) 30 (8.6) 167 (9.6)
Native Hawaiian or other Paciﬁc Islander 9 (3.6) 35 (3.1) 11 (3.1) 55 (3.2)
White 186 (74.4) 841 (74.3) 266 (76.0) 1293 (74.7)
Other 10 (4.0) 78 (6.9) 22 (6.3) 110 (6.4)
Age (years)
n 250 1132 350 1732
Mean (SD) 55.7 (12.9) 51.2 (11.8) 48.9 (11.2) 51.4 (11.9)
Body mass index (kg/m2)
n 249 1131 347 1727
Mean (SD) 33.04 (6.8) 34.39 (7.5) 35.45 (8.1) 34.41 (7.7)
sUA (mg/dL)
n 250 1132 350 1732
Mean (SD) 8.4 (1.7) 8.8 (1.7) 8.9 (1.6) 8.8 (1.7)
Duration of gout diagnosis (years)
n 250 1132 350 1732
Mean (SD) 8.89 (8.3) 9.92 (9.0) 12.14 (10.0) 10.22 (9.2)
Presence of tophi at baseline [n (%)]
Yes 36 (14.4) 167 (14.8) 90 (25.7) 293 (16.9)
No 214 (85.6) 965 (85.2) 260 (74.3) 1439 (83.1)
Number of gout ﬂares requiring treatment in prior year [n (%)]
0 22 (8.8) 71 (6.3) 10 (2.9) 103 (5.9)
1 13 (5.2) 95 (8.4) 15 (4.3) 123 (7.1)
2 60 (24.0) 222 (19.6) 48 (13.7) 330 (19.1)
3 56 (22.4) 211 (18.6) 71 (20.3) 338 (19.5)
4 27 (10.8) 148 (13.1) 42 (12.0) 217 (12.5)
Z5 72 (28.8) 385 (34.0) 164 (46.9) 621 (35.9)
Renal function at baseline (estimated CrCl in mL/min)
Z90 83 (33.2) 533 (47.1) 197 (56.3) 813 (46.9)
60 to o90 94 (37.6) 442 (39.0) 118 (33.7) 654 (37.8)
30 to o60 70 (28.0) 154 (13.6) 33 (9.4) 257 (14.8)
o30a 3 (1.2) 2 (0.2) 1 (0.3) 6 (0.3)
Missing 0 1 (0.1) 1 (0.3) 2 (0.1)
CrCl, creatinine clearance; sUA, serum uric acid.
a An estimated CrCl o 30 mL/min at screening was an exclusion criterion. In subjects with moderate renal impairment, creatinine clearance may have dropped below
30 mL/min when measured at baseline.
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the o300-mg category (49.6%) than 300-mg (26.7%) or 4300-mg
(19.4%) categories. Reasons for discontinuation are reported in
Figure 2.Table 3
Number (%) of patients at ﬁnal daily allopurinol dose categorized by baseline dose
Fin
Baseline dose (mg/d) 0 40–50 450–100 4100–200
r50 (n ¼ 25) 0 (0) 1 (4) 0 (0) 2 (8.0)
450–100 (n ¼ 566) 0 (0) 1 (0.2) 38 (6.7) 88 (15.5)
4100–200 (n ¼ 395) 1 (0.3) 0 (0) 4 (1.0) 129 (32.7)
4200–300 (n ¼ 662) 0 (0) 0 (0) 1 (0.2) 8 (1.2)
4300–400 (n ¼ 62) 0 (0) 0 (0) 0 (0) 0 (0)
4400–500 (n ¼ 11) 0 (0) 0 (0) 0 (0) 0 (0)
4500–600 (n ¼ 8) 0 (0) 0 (0) 0 (0) 0 (0)
600 (n ¼ 3) 0 (0) 0 (0) 0 (0) 0 (0)
Bold values¼ percentage of patients in same category in last visit as at baseline. Those ab
(non-italics) were at a lower dose level than at baseline.Prophylaxis for gout ﬂares was taken by 1719 (99.2%) patients
(Fig. 2); the most common was colchicine (n ¼ 1468), followed by
an NSAID (n ¼ 209), both colchicine and NSAID (n ¼ 41), or
another (n ¼ 1). Concomitant medication use was high (99.9%);al allopurinol dose (mg/d)
4200–300 4300–400 4400–500 4500–600 4600
17 (68.0) 4 (16.0) 0 (0) 1 (4.0) 0 (0)
344 (60.8) 72 (12.7) 11 (1.9) 11 (1.9) 1 (0.2)
209 (52.9) 31 (7.8) 14 (3.5) 5 (1.3) 2 (0.5)
557 (84.1) 55 (8.3) 19 (2.9) 14 (2.1) 8 (1.2)
2 (3.2) 34 (54.8) 17 (27.4) 7 (11.3) 2 (3.2)
0 (0) 1 (9.1) 8 (72.7) 0 (0) 2 (18.2)
2 (25.0) 0 (0) 0 (0) 5 (62.5) 1 (12.5)
0 (0) 0 (0) 0 (0) 0 (0) 3 (100)
ove the diagonal (italics) were at a higher dose level, and those below the diagonal
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410% of patients included lisinopril (16.7%), acetylsalicylic acid
(16.2%), and simvastatin (10.9%).
Primary end point
Treatment-emergent adverse events
In total, 955 patients (55.1%) experienced a TEAE, including 185
patients (10.7%) with a TEAE reported possibly related to allopur-
inol and 183 (10.6%) with a TEAE possibly related to ﬂare
prophylaxis (Table 4). The most common TEAEs in the total
population were upper respiratory tract infection, diarrhea, and
arthralgia. There was an apparent positive dose relationship for
TEAEs of upper respiratory tract infection, back pain, and head-
ache. Nephrolithiasis was reported in 7 (0.4%) patients, all in the
300-mg allopurinol category. Rash incidence was low overall (1.5%)
and AHS was not reported (Table 4).
The incidence of TEAEs possibly related to allopurinol was the
highest in the o300-mg (15.2%) and the lowest in the 300-mg
category (9.5%). The most common TEAEs possibly related to
allopurinol (in o300-, 300-, and 4300-mg categories, respec-
tively) were alanine aminotransferase increase (2.0%, 1.1%, and
2.0%), diarrhea (1.2%, 1.1%, and 2.0%), and rash (2.0%, 0.8%, and
0.3%). TEAEs possibly related to allopurinol occurred at a lower
incidence in patients receiving allopurinol at screening (7.6%) than
in those not receiving ULT (12.1%). TEAEs possibly related to
allopurinol occurred at similar incidences in categories divided
by baseline renal function.
Serious AEs (SAEs) occurred in 51 (2.9%) patients, including
three patients with pneumonia, three with acute myocardial
infarction, and two patients each with cellulitis, diverticulitis,Table 4
TEAEs and TEAEs possibly related to allopurinol experienced by Z1% in any dosing cat
Category
o300 mg (n ¼
n (%)
Any TEAE 124 (49.6)
TEAE with Rheumatology Common Toxicity Criteria Grade 3 or 4 14 (5.6)
TEAE possibly related to allopurinol 38 (15.2)
TEAE possibly related to prophylaxis 32 (12.8)
Serious TEAE 8 (3.2)
TEAE with outcome of death 1 (0.4)
TEAE leading to allopurinol withdrawal or study discontinuation 27 (10.8)
TEAE leading to prophylaxis switch or withdrawal 27 (10.8)
Most frequent TEAEs (incidence 41.0% of total subjects)
Upper respiratory tract infection 4 (1.6)
Diarrhea 10 (4.0)
Arthralgia 4 (1.6)
Nasopharyngitis 8 (3.2)
Blood creatine phosphokinase increased 9 (3.6)
Back pain 2 (0.8)
Pain in extremity 10 (4.0)
Hypertension 6 (2.4)
Headache 4 (1.6)
Alanine aminotransferase increased 5 (2.0)
Bronchitis 3 (1.2)
Inﬂuenza 1 (0.4)
Rash 6 (2.4)
Muscle strain 2 (0.8)
Nausea 4 (1.6)
Aspartate aminotransferase increased 4 (1.6)
Nasal congestion 2 (0.8)
Musculoskeletal pain 1 (0.4)
Urinary tract infection 3 (1.2)
Liver function test abnormal 3 (1.2)
TEAE, treatment-emergent adverse events.prostate cancer, gout, acute coronary syndrome, atrial ﬁbrillation,
atrial ﬂutter, supraventricular tachycardia, and small intestinal
obstruction. One patient in the o300-mg category and two
patients in the 300-mg category had an SAE with outcome of
death, categorized respectively as sudden death, pulmonary embo-
lism, and death due to natural causes. No SAEs were considered
possibly related to allopurinol or ﬂare prophylaxis.
The incidence of TEAEs leading to allopurinol withdrawal or
study discontinuation was 4.3% overall, with the highest rate in
the o300-mg category (10.8%), followed by 300-mg (3.6%) and
4300-mg categories (1.7%). The most common TEAEs associated
with allopurinol withdrawal or study discontinuation were rash
(10 patients) and diarrhea, alanine aminotransferase increase, and
gamma-glutamyl transferase increase (six patients each). TEAEs
leading to withdrawal of ﬂare prophylaxis or switch occurred at an
incidence of 5.4% overall, with the highest frequency in the o300-
mg category (10.8%), followed by 300-mg (4.9%) and 4300-mg
categories (3.1%).
There were no consistent clinically meaningful changes in
laboratory values during the study, including liver function param-
eters (alanine aminotransferase, alkaline phosphatase, aspartate
aminotransferase, and bilirubin). Modest but consistent decreases
from baseline were observed in mean values for platelets, leuko-
cytes, neutrophils, and percent neutrophils/leukocytes. Mean
decreases in these parameters were greater in patients who received
colchicine than NSAIDs for ﬂare prophylaxis. No clinically mean-
ingful changes were reported for urinalysis results or vital signs.
The CV adjudication committee reported a high rate of con-
cordance with events reported by the study-site investigators.
The overall incidence of MACE (CV death, nonfatal myocardial
infarction, and nonfatal stroke) was 0.58%, with an incidence rateegory of the study population
Maximum allopurinol daily dose
250), 300 mg (n ¼ 1132),
n (%)
4300 mg (n ¼ 350),
n (%)
Total (N ¼ 1732),
n (%)
623 (55.0) 208 (59.4) 955 (55.1)
60 (5.3) 21 (6.0) 95 (5.5)
107 (9.5) 40 (11.4) 185 (10.7)
110 (9.7) 41 (11.7) 183 (10.6)
34 (3.0) 9 (2.6) 51 (2.9)
2 (0.2) 0 3 (0.2)
41 (3.6) 6 (1.7) 74 (4.3)
56 (4.9) 11 (3.1) 94 (5.4)
65 (5.7) 31 (8.9) 100 (5.8)
49 (4.3) 18 (5.1) 77 (4.4)
39 (3.4) 12 (3.4) 55 (3.2)
32 (2.8) 13 (3.7) 53 (3.1)
24 (2.1) 15 (4.3) 48 (2.8)
28 (2.5) 15 (4.3) 45 (2.6)
26 (2.3) 8 (2.3) 44 (2.5)
28 (2.5) 9 (2.6) 43 (2.5)
24 (2.1) 13 (3.7) 41 (2.4)
21 (1.9) 12 (3.4) 38 (2.2)
18 (1.6) 8 (2.3) 29 (1.7)
16 (1.4) 9 (2.6) 26 (1.5)
16 (1.4) 4 (1.1) 26 (1.5)
19 (1.7) 4 (1.1) 25 (1.4)
15 (1.3) 5 (1.4) 24 (1.4)
14 (1.2) 5 (1.4) 23 (1.3)
14 (1.2) 6 (1.7) 22 (1.3)
8 (0.7) 11 (3.1) 20 (1.2)
15 (1.3) 2 (0.6) 20 (1.2)
14 (1.2) 2 (0.6) 19 (1.1)
Table 5
Patients who achieved serum uric acid targets by visit
Visit Maximum allopurinol daily dose
Serum uric acid target o300 mg (n ¼ 250),
n (RESP) [95% CI on RESP]
300 mg (n ¼ 1132),
n (RESP) [95% CI on RESP]
4300 mg (n ¼ 350),
n (RESP) [95% CI on RESP]
Total (N ¼ 1732),
n (RESP) [95% CI on RESP]
Month 1
o6 mg/dL 78 (0.31) [0.26, 0.37] 348 (0.31) [0.28, 0.34] 74 (0.21) [0.17, 0.26] 500 (0.29) [0.27, 0.31]
o5 mg/dL 18 (0.07) [0.04, 0.11] 105 (0.09) [0.08, 0.11] 19 (0.05) [0.03, 0.08] 142 (0.08) [0.07, 0.10]
o4 mg/dL 1 (0.004) [0.00, 0.02] 11 (0.01) [0.00, 0.02] 4 (0.01) [0.00, 0.03] 16 (0.01) [0.01, 0.01]
Month 2
o6 mg/dL 75 (0.30) [0.24, 0.36] 448 (0.40) [0.37, 0.42] 122 (0.35) [0.30, 0.40] 645 (0.37) [0.35, 0.40]
o5 mg/dL 23 (0.09) [0.06, 0.13] 129 (0.11) [0.10, 0.13] 41 (0.12) [0.09, 0.16] 193 (0.11) [0.10, 0.13]
o4 mg/dL 1 (0.004) [0.00, 0.02] 17 (0.02) [0.01, 0.02] 7 (0.02) [0.01, 0.04] 25 (0.01) [0.01, 0.02]
Month 3
o6 mg/dL 77 (0.31) [0.25, 0.37] 442 (0.39) [0.36, 0.42] 145 (0.41) [0.36, 0.47] 664 (0.38) [0.36, 0.41]
o5 mg/dL 16 (0.06) [0.04, 0.10] 139 (0.12) [0.10, 0.14] 41 (0.12) [0.09, 0.16] 196 (0.11) [0.10, 0.13]
o4 mg/dL 1 (0.004) [0.00, 0.02] 13 (0.01) [0.01, 0.02] 8 (0.02) [0.01, 0.04] 22 (0.01) [0.01, 0.02]
Month 4
o6 mg/dL 71 (0.28) [0.23, 0.34] 431 (0.38) [0.35, 0.41] 159 (0.45) [0.40, 0.51] 661 (0.38) [0.36, 0.40]
o5 mg/dL 18 (0.07) [0.04, 0.11] 145 (0.13) [0.11, 0.15] 52 (0.15) [0.11, 0.19] 215 (0.12) [0.11, 0.14]
o4 mg/dL 1 (0.004) [0.00, 0.02] 20 (0.02) [0.01, 0.03] 10 (0.03) [0.01, 0.05] 31 (0.02) [0.01, 0.03]
Month 5
o6 mg/dL 70 (0.28) [0.23, 0.34] 425 (0.38) [0.35, 0.40] 167 (0.48) [0.42, 0.53] 662 (0.38) [0.36, 0.41]
o5 mg/dL 18 (0.07) [0.04, 0.11] 135 (0.12) [0.10, 0.14] 68 (0.19) [0.15, 0.24] 221 (0.13) [0.11, 0.14]
o4 mg/dL 3 (0.01) [0.00, 0.03] 13 (0.01) [0.01, 0.02] 15 (0.04) [0.02, 0.07] 31 (0.02) [0.01, 0.03]
Month 6
o6 mg/dL 56 (0.22) [0.17, 0.28] 396 (0.35) [0.32, 0.38] 169 (0.48) [0.43, 0.54] 621 (0.36) [0.34, 0.38]
o5 mg/dL 20 (0.08) [0.05, 0.12] 129 (0.11) [0.10, 0.13] 67 (0.19) [0.15, 0.24] 216 (0.13) [0.11, 0.14]
o4 mg/dL 2 (0.01) [0.00, 0.03] 24 (0.02) [0.01, 0.03] 15 (0.04) [0.02, 0.07] 41 (0.02) [0.02, 0.03]
CI, conﬁdence interval; RESP, response rate (proportion of patients who met serum uric acid targets).
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non-MACE CV end points was 0.75%.Secondary end points
sUA-lowering efﬁcacy of allopurinol
At month 6, 35.9% of patients had sUA o 6.0 mg/dL. A greater
proportion of patients met this target in the 4300-mg category
(48.3%) than 300-mg (35.0%) and o300-mg categories (22.4%)
(Table 5). The CIs for response rate in Table 5 demonstrate the
wide interpatient variability in each dosing category. Mean (SD)
decreases in sUA from baseline to month 6 were 1.5 (1.84), 2.4
(1.97), and 2.7 (2.04) mg/dL in the o300-, 300-, and 4300-mg
categories, respectively, representing decreases of 16.6%, 25.1%,
and 28.7%.
sUA targets of o5 mg/dL and o4 mg/dL were met by 12.5% and
2.4% of patients, respectively, at month 6 (Table 5); the proportions
of patients meeting targets of o5 and o4 mg/dL were the highest
in the 4300-mg and the lowest in the o300-mg category.
Monthly sUA assessments showed that the lowest proportion
of patients meeting the sUA target of o6 mg/dL was in month 1
(28.9%), while months 26 had higher and similar proportions of
patients meeting target (range: 35.9–38.3%) (Table 5). The propor-
tions of patients meeting this sUA target were generally similar
across subgroups categorized by race, type of gout ﬂare prophy-
laxis, number of gout ﬂares in the prior year, presence of tophi at
baseline, and use of concomitant diuretics at baseline (Table 6).
Older patients (Z65 years), women, non-users of allopurinol at
screening, patients with baseline sUA, 7 to o8 mg/dL (versus
other dose groups), and patients with lower baseline renal
function showed higher goal-range sUA-lowering response rates
than other subgroups.
Additional efﬁcacy analyses were performed post hoc to deter-
mine the proportions of patients who met the sUA target ofo6.0 mg/dL when categorized by ﬁnal allopurinol dose (rather
than the highest dose during study, as described above). At the
time of last dose, 43.0% of patients receiving a ﬁnal dose 4200–
300 mg/d and 54.1% of patients receiving a ﬁnal dose 4300 mg/d
met the sUA target (Fig. 3). Safety analyses were not performed on
the population categorized by ﬁnal allopurinol dose.Incidences of gout ﬂares requiring treatment
Approximately one-third of patients (33.4%) experienced one or
more gout ﬂares requiring treatment, with a greater proportion in
the 4300-mg (44.3%) than 300-mg (33.7%) or o300-mg (16.4%)
categories. For all three dosing categories, highest incidences of
gout ﬂares requiring treatment were in month 1 and declined over
subsequent months.
Proportions of patients experiencing gout ﬂares requiring
treatment were greater in those with higher baseline sUA, higher
baseline CrCl, non-users of allopurinol at screening, and users of
NSAID versus colchicine prophylaxis during study (Table 7).Discussion
Although allopurinol is a ﬁrst-line ULT in patients with gout
[5,6], sUA targets are frequently not achieved, possibly due to
perceived intolerability of doses above 300 mg [6,12,13,17–19].
Study data on the safety and efﬁcacy of allopurinol at doses above
300 mg/d are limited [20,21].
LASSO was a large, open-label, 6-month study of allopurinol
under conditions where investigators were encouraged to titrate
to optimal, medically appropriate doses. The 350 patients treated
with 4300 mg daily of allopurinol are, to our knowledge, the
largest cohort to date of individuals receiving daily doses at these
levels. Mean total days of dosing were similar in the 4300- and
300-mg categories and lower in the o300-mg category, which
Table 6
Patients who achieved serum uric acid target o6.0 mg/dL by month 6: categoriza-
tion by subgroups
Patient subgroup Patients meeting sUA target,
n/N (RESP) [95% CI on RESP]
Age
Z65 years 109/249 (0.44) [0.38–0.50]
o65 years 512/1483 (0.35) [0.32–0.37]
Gender
Female 49/118 (0.42) [0.33–0.51]
Male 572/1614 (0.35) [0.33–0.38]
Race
White 476/1293 (0.37) [0.34–0.40]
Non-white 145/439 (0.33) [0.29–0.38]
Type of gout ﬂare prophylaxis
Colchicine 543/1508 (0.36) [0.34–0.38]
NSAID 87/253 (0.34) [0.29–0.41]
Number of gout ﬂares in prior year
n ¼ 2 112/303 (0.37) [0.32–0.43]
n 4 2 509/1429 (0.36) [0.33–0.38]
Tophi at baseline
Yes 104/293 (0.36) [0.30–0.41]
No 517/1439 (0.36) [0.33–0.38]
Allopurinol use at screening
Yes 173/555 (0.31) [0.27–0.35]
No 448/1177 (0.38) [0.35–0.41]
Concomitant diuretics at baseline
Yes 101/293 (0.35) [0.29–0.40]
No 520/1439 (0.36) [0.34–0.39]
sUA at baseline
Z10.0 mg/dL 109/388 (0.28) [0.24–0.33]
8.0 to o10.0 mg/dL 321/828 (0.39) [0.35–0.42]
7.0 to o8.0 mg/dL 143/288 (0.50) [0.44–0.56]
6.0 to o7.0 mg/dL 44/159 (0.28) [0.21–0.35]
Renal function at baseline
CrCl Z 90 mL/min 260/813 (0.32) [0.29–0.35]
CrCl: 60 to o90 mL/min 253/654 (0.39) [0.35–0.43]
CrCl: 30 to o60 mL/min 105/257 (0.41) [0.35–0.47]
CI, conﬁdence interval; RESP, response rate (proportion of patients who met serum
uric acid target); n/N, number of subjects achieving target/number of eligible
patients in subgroup.
Table 7
Patients who experienced gout ﬂares requiring treatment: categorization by
subgroups
Patient subgroup Patients with 1 or more gout ﬂares
n/N (RESP) [95% CI on RESP]
sUA at baseline
Z10.0 mg/dL 168/388 (0.43) [0.38–0.48]
8.0 to o10.0 mg/dL 281/828 (0.34) [0.31–0.37]
7.0 to o8.0 mg/dL 86/288 (0.30) [0.25–0.36]
6.0 to o7.0 mg/dL 37/159 (0.23) [0.17–0.31]
Renal function at baseline
CrCl Z 90 mL/min 292/813 (0.36) [0.33–0.39]
CrCl: 60 to o90 mL/min 214/654 (0.33) [0.29–0.36]
CrCl: 30 to o60 mL/min 70/257 (0.27) [0.22–0.33]
Allopurinol use at screening
Yes 154/555 (0.28) [0.24–0.32]
No 424/1177 (0.36) [0.33–0.39]
User of colchicine versus NSAID prophylaxis during study
Colchicine 494/1508 (0.33) [0.30–0.35]
NSAID 100/250 (0.40) [0.34–0.46]
RESP, response rate (proportion of patients who met serum uric acid target).
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the study.
Allopurinol was generally well tolerated during the 6-month
study, with low rates of TEAEs possibly related to allopurinol and
discontinuation-related TEAEs. The types of TEAEs were consistent100
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Fig. 3. Proportion of patients with sUA o 6.0 mg/dLwith the known proﬁle of allopurinol [20,22], incidences of rash
were low, and there were no cases of AHS, which typically has an
onset within days to weeks after initiation of allopurinol [23]. The
current data suggest that the 6-month rate of serious CV AEs in
this study of patients with gout ranged from 1.0% to 1.5% during
treatment with allopurinol, representing an overall incidence rate
for MACE of 1.42/100 patient-years. These rates of CV events are
broadly similar to those reported in other long-term follow-up
studies of patients with gout, a population recognized to be at
elevated CV risk [13,24].
Incidences of TEAEs possibly related to allopurinol and of
discontinuation-related TEAEs were the highest in the o300-mg
category, while the highest dosing category (4300 mg) had
intermediate/lowest incidences. A potential explanation is that
patients who developed intolerance early in the study were
withdrawn before allopurinol dose uptitration. TEAEs occurred at
a lower incidence in patients receiving allopurinol at baseline
compared with those not receiving ULT, which likely reﬂects the
demonstration of tolerability to allopurinol in the former group
prior to study entry. TEAEs, including upper respiratory tract
infection, back pain, and headache, occurred at a higher frequency
in the 4300-mg than o300-mg category. Whether this observa-
tion indicates a dose relationship or the effect of longer duration or
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categorized by their ﬁnal daily allopurinol dose.
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baseline CrCl o 60 mL/min was greater in the o300-mg category
than 300-mg and 4300-mg categories. This difference is most
likely a reﬂection of clinical practice, as investigators were less
likely to uptitrate allopurinol in patients with lower levels of renal
function.
Previous studies have shown that achievement of the target
sUA range is associated with gout control [25,26]. In LASSO, only
35.9% of patients met the sUA target of o6 mg/dL at 6 months,
which is consistent with response rates reported previously for
allopurinol at a dose of 300 mg [14,17,21]. Studies of allopurinol at
higher doses have reported greater rates of achievement of target
sUA [21,22]. Although demonstration of a dose–response effect is
not possible in LASSO because of the nature of the study with
variable dose titration, it is notable that highest response rates
(48.3%) were in the 4300-mg category and lowest rates (22.4%) in
the o300-mg category. Even at the highest allopurinol doses, a
proportion of patients showed no response, perhaps indicative
that some patients do not beneﬁt from increased doses of this
xanthine oxidase inhibitor. Finally, while rates of patient self-
reported adherence were high in LASSO, oxypurinol levels were
not assessed to conﬁrm compliance. This is consistent with usual
clinical practice, in which drug concentrations are not routinely
monitored.
The success rate for achieving sUA targets in gout is increased if
physicians closely follow dose-titration guidelines, and patients
are informed of the beneﬁts of continuing treatment [22,27].
Despite the recommendation to titrate allopurinol doses to an
sUA target range in LASSO, it is notable that physicians readily
titrated allopurinol from low doses to 300 mg daily, but they much
less frequently advanced the dose beyond 300 mg.
Two additional issues for comment in the LASSO study are the
potential inﬂuence of acetylsalicylic acid intake on sUA and the
impact of allopurinol on occurrences of back pain. Use of acetylsa-
licylic acid is known to elevate sUA. Acetylsalicylic acid was taken
by 16.2% of patients in LASSO, but in the majority of cases at low
dose as an antithrombotic. Acetylsalicylic acid taken at this dose
would be expected to have minimal, if any, effect on sUA or ﬂares
in a gout population treated with allopurinol and/or a URAT1
inhibitor [6,28–30]. Back pain was reported in 2.6% of patients. It is
not possible in LASSO to assess whether kidney stones (reported in
0.4% of patients) or changes in sUA were related to occurrences of
back pain. However, as allopurinol does not cause “resaturation” in
the kidneys but rather decreases nephrolithiasis [31], it would not
be expected that allopurinol treatment contributed to the develop-
ment of back pain. It is more likely that back pain in this
predominantly male, middle-aged population was musculoskeletal
in origin.
Limitations of the LASSO study include the open-label study
design, lack of information on why subjects were not dose-titrated
when not at goal, the different durations of treatment between
dosing categories, the exclusion of patients with severely impaired
renal function (i.e., CrCl o 30 mL/min), and the use of concom-
itant medications so that safety and efﬁcacy results cannot be
attributed solely to allopurinol. Patients who showed a lack of
response to allopurinol after at least 8 weeks, or who were
intolerant to allopurinol, were eligible for participation in phase
3 studies of lesinurad; this may have inﬂuenced discontinuation
rates, limiting assessments of efﬁcacy and safety. Finally, the
population comprised both patients already receiving allopurinol
and those not on ULT at the time of study entry (including those
who had or had not received ULT in the past). A larger number of
patients who are conﬁrmed never to have received allopurinol
may be needed to detect rare TEAEs such as hypersensitivity
reactions. The strengths of the LASSO study are its large patientpopulation, long treatment duration, and use of allopurinol in
regimens that reﬂect clinical practice.
In conclusion, this large multicenter study identiﬁed no new
safety signals for allopurinol at doses including 4300 mg daily, in
agreement with previous studies [20–22]. There were minor
differences in the incidence of TEAEs possibly related to allopur-
inol among the dosing categories (o300, 300, and 4300 mg
daily), while rates of adherence were high for all doses. Despite
encouragement to treat to target, 300 mg daily was the most
commonly used dose, and signiﬁcant proportions of patients did
not achieve target sUA. The results of LASSO may prove valuable
for future trials of allopurinol as monotherapy and in combination
with current and emerging therapies in the treatment of gout.Clinical signiﬁcance
Before the LASSO study, there were limited data on the safety
and efﬁcacy of dose-titrated allopurinol in gout, particularly at
doses exceeding 300 mg/d. LASSO was a large open-label, 6-month
study in which investigators were encouraged to titrate allopurinol
doses to achieve a target serum uric acid concentration (sUA)
o 6.0 mg/dL. We observed that the dose-titration strategy was
generally well tolerated, including at allopurinol doses 4300 mg
daily. A greater proportion of patients met the sUA target in
4300-mg than 300-mg and o300-mg allopurinol dose catego-
ries. However, despite encouragement to treat to target, 300 mg
daily was the most commonly used dose and signiﬁcant propor-
tions of patients did not achieve target sUA.Acknowledgments
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